From USFDA
Zydus Cadila has received final approval from the USFDA to market Clobetasol Propionate Ointment USP, 0.05%. The drug is indicate to treat variety of skin conditions (e.g. eczema, dermatitis, allergies, rash). It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
